Alnylam Pharmaceuticals
Alnylam Pharmaceuticals develops RNAi therapeutics to silence genes causing human disease and offers a range of patient services, including genetic testing and counseling.
Company Overview
Alnylam Pharmaceuticals is at the forefront of developing RNA interference (RNAi) therapeutics to silence genes that cause human diseases. The company has pioneered RNAi therapeutics as a novel class of medicines. Its focus spans genetic medicines, cardiometabolic diseases, infectious diseases, and central nervous system and ocular diseases. The company operates globally and is committed to corporate responsibility and transparency.
RNAi Therapeutics Pipeline
Alnylam Pharmaceuticals boasts a robust pipeline of investigational RNAi therapeutics aimed at treating a variety of conditions. The pipeline includes candidates targeted at genetic diseases, cardiometabolic disorders, infectious diseases, and diseases affecting the central nervous system and eyes. The company remains dedicated to advancing these investigational therapies to provide new treatment options for patients.
Patient Services
Alnylam Pharmaceuticals offers an array of patient services, including genetic testing and counseling. These services are designed to assist patients and healthcare providers in understanding and managing genetic conditions. Through Alnylam Act, the company offers no-charge genetic testing and counseling for specific conditions, ensuring accessible support for patients in need.
Global Operations
Alnylam Pharmaceuticals operates in multiple countries around the world, bringing its innovative RNAi therapeutics to a global patient population. The company's international presence facilitates the development and distribution of its therapies, and underscores its commitment to addressing unmet medical needs on a global scale.
Advocacy and Corporate Responsibility
Alnylam Pharmaceuticals is dedicated to corporate responsibility and advocacy. The company engages in various initiatives, including providing impact grants and supporting investigator-initiated studies. These efforts reflect Alnylam's commitment to making a positive impact on the healthcare community and advancing scientific research.